Please assess the completion status of the following clinical trial:

Trial Title: A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females ages 18 - 80~* Chronic kidney disease (CKD) - eGFR 15 to \< 60 mL/min/1.73m2 at screening~* Hyperkalemia, defined as a serum potassium value of 5.1 to \< 6.5 mEq/L at screening~* Taking either an Angiotensin-Converting Enzyme (ACE) Inhibitor, an Angiotensin II receptor blocker (ARB), or an aldosterone antagonist (AA) medication~* Informed consent given~Exclusion Criteria:~* Participants with auto-immune related chronic kidney disease such as lupus nephritis or renal scleroderma/scleroderma renal crisis, or mixed connective tissue disease with renal involvement~* Participants with uncontrolled Type 1 diabetes, defined as or a HbA1c \> 10.0 %, or hospitalization to treat hyper- or hypo-glycemia in the past 3 months within the previous 6 months in participants with Type 2 diabetes~* Participants with severe heart failure, defined as NYHA (New York Heart Association) class IV~* Participants with major surgery including thoracic and cardiac, in the past 3 months, or participants with heart or kidney transplant~* Participants with significant cardiovascular or cerebrovascular events in the past 2 months, such as cardiac arrest, myocardial infarction, or stroke~* Participants with BMI ≥ 40 kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Patiromer (Type: ACTIVE_COMPARATOR): Patiromer was administered twice a day as a powder mixed with water.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo was administered twice a day as a powder mixed with water.

Based on this trial design, predict the completion outcome and termination type (if applicable).